MASSDEVICE ON CALL — BioMimetic Therapeutics (NSDQ:BMTI) cut 25% of its workers in hopes of saving some cash in focusing on getting FDA pre-market approval for its Augment bone graft.
The federal watchdog agency’s advisory panel recommended approving the treatment in May 2011, after releasing a dim summary of the pre-market approval application that sunk BMTI shares by more than 35%.
Mela Sciences (NSDQ:MELA) announced an expanded 3-year manufacturing contract with long-time supplier Askion GmbH for production of the MelaFind devices.
MelaFind, the company’s flagship product, is a handheld, non-invasive melanoma detection and identification system designed to help a physician decide whether or not to biopsy a suspect patch of skin.
Terumo Americas Holding, the U.S. subsidiary of Japan’s Terumo Corp., acquired Onset Medical Corp., makers of access sheath technology for multiple minimally invasive applications.
Terumo is a $4 billion a year company with sales and operations in more than 160 countries, according to a press release. The value of the acquisition wasn’t made public.
C.R. Bard (NYSE:BCR) acquired Minneapolis-based angioplasty balloon maker Lutonix Inc. for $325 million.
The merger, announced during Bard’s 2012 guidance update conference call, grants Lutonix $225 million up front with another $100 million when Lutonix achieves pre-market approval for its drug-coated balloons.
Orthopedic company Symmetry Medical (NYSE:SMA) signed a definitive agreement to acquire the surgical instrument business of Johnson & Johnson (NYSE:JNJ) subsidiary Codman & Shurtleff for $165 million cash.
Symmetry plans to integrate its current hospital direct business, Specialty Surgical Instrumentation, with Codman’s line of surgical instruments.
Italian medical device maker Sorin Group (BIT:SRN) invested in early-stage company Enopace Biomedical to fund the development of a neuromodulation system for patients with congestive heart failure.
Enopace’s technology consists of an implantable neurostimulator that increases heart efficiency by reducing the workload placed on the left ventricle. Sorin Group’s $7 million investment will finance clinical studies and ongoing product development.
NuVasive (NSDQ:NUVA) closed its $80 million pickup of Impulse Monitoring Inc. last week, according to a filing with the federal Securities & Exchange Commission.
The deal, which closed Oct. 7, saw IMI’s shareholders receive nearly $40.5 million in cash and more than 2.3 million shares of NuVasive common stock with an aggregate value of about $40.5 million (per NUVA’s Oct. 6 closing share price of $17.32).